• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » MassDevice Q&A: Michael Phalen

MassDevice Q&A: Michael Phalen

June 10, 2009 By Brad Perriello

Michael Phalen, president of Boston Scientific Corp.‘s endoscopy division, began his long tenure at the Natick devices giant in 1988 as a sales rep. After several crossings between the outside sales world and inside marketing positions, he was named president of the endoscopy operation in 2001.*

It was a good time to get into endoscopy, Phalen tells MassDevice, as physicians began using the technology to provide previously unheard of, minimally invasive views of the workings of the human body.

We chatted with Phalen recently to discuss developments in his division, its “patients first” philosophy, what’s on the horizon for endoscopy in general and his views on the biggest challenges facing the medical device industry.

MassDevice: What makes the medical device industry a good fit for you?

Michael Phalen: I got exposed to endoscopy in mid- to late-1980s. It was just a fascinating thing to watch, because physicians were making use of endoscopes to actually see inside the body and make sense of it with a less-invasive intervention. It’s proven to be a very good decision on my part, because the endoscopy business at Boston Scientific has become a very large business and a key component of the corporation.

MassDevice: What’s the biggest leadership lesson you’ve learned?

MP: We have to recognize that we play a role in the healthcare industry. Physicians and nurses rely heavily on our devices to try and help their patients. People have our devices used on them and we have to have the patient first and foremost in mind and focus on what will benefit the patient. That’s a core value of Boston Scientific Endoscopy. We really do try to practice that in all of our teaching and training.

MassDevice: Obviously the FDA’s recent 510(k) approval of the SpyGlass device for cholangioscopy is big news for the division. Can you give us a quick overview of the device?

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/featureArt/SpyGlass_300x200.jpg}MP: This is a device that’s used in what we refer to as “pancreatico-biliary intervention” — that is, interventions involving the gallbladder, common bile duct and pancreas. Pancreatic cancers are really very difficult, challenging diseases for the medical folks to engage. SpyGlass is the latest set of tools we’ve developed. It was commercialized two years ago for the common bile duct. It’s a catheter that has a little imaging component to it that allows physicians to put it through the pancreatic duct and into the pancreas. It can be used to take biopsies or we have a number of accessories they can use to break up a stone or perform other procedures.

Cholangioscopy for 15 or 20 years was not used very often because it takes two doctors to perform the operation. We made it more of a catheter-based procedure with steerability so a single physician can operate it.

MassDevice: What’s on the horizon for the endoscopy division? What do you see as the hottest trends today in the field?

MP: There are a number of areas under investigation today in the space. There’s definitely a trend of having more and more surgeons utilize flexible endoscopy as part of their interventional tool kit. We see an expanding customer call for medical and surgical endoscopy.

There’s been a lot of press in the last couple of years about “natural orifice surgery.” Endoscopy’s beginning to be used more as a surgical tool through natural orifices. That’s an area that’s very interesting and continues to be studied by a lot of companies and researchers.

And there’s also a lot of interest in looking at endoscopy to help treat obese patients in bariatric procedures.

Endoscopy in general is growing throughout the world. We have an aging worldwide population, more and more people are living longer, and obviously the GI tract has a fair amount of challenges.

MassDevice: What’s been the biggest lesson you’ve learned during this recession? What’s the takeaway?

MP: We have to remain competitive in everything we do. We do everything we can as a division to continue to produce high-quality devices that meet clinical needs at a fair and equitable cost. Our business is largely still centered around patients that really have to have interventions. If you have a bleeding ulcer in your colon, it’s not like you can put that treatment off. We haven’t seen a significant impact yet. Certainly it’s gotten more competitive.

MassDevice: How about the future of selling medical devices, which is still very reliant on sales reps visiting doctors. As these opportunities become more difficult with the rising prevalence of gift bans, how will companies adapt their sales processes?

MP: We’re still trying to understand what the rules are. A lot of this centers around conferences and meetings — that’s been throttled back pretty heavily over the last several years. Time will tell what really turns out to be a change, in terms of how healthcare is governed in the U.S.

The thing I worry about the most is innovation. We try to work closely with physicians to identify unmet needs. How we do that going forward is going to meet with substantial change.

MassDevice: Aside from gift bans, are there other rules or regulations that have you concerned?

MP: There are a lot of forces at play that could fundamentally change the dynamics of this industry, in that industry supports a lot of research and innovation. You do worry about it. I understand that there’s a need to be invested in change and we want to do the right thing, but you wonder about unintended consequences.

I worry about the industry as a whole losing its edge. We lead the world in medical device innovation. I worry about it ultimately affecting patient care. We’ll see how that unfolds. It’s a big issue, but the idea of how the industry interacts with healthcare providers is probably the biggest sea change we’ll face for the next decade or so.

*Correction, Aug. 27, 2010: This article originally stated that Phalen was named president of the endoscopy division in 1991. Return to the corrected sentence.

Filed Under: Business/Financial News, Endoscopic Tagged With: MassDevice Q&A

In case you missed it

  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D
  • Abbott reports positive data on heart valve therapies
  • OncoRes Medical raises another $12.5M
  • NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia
  • Inogen appoints Agnes Lee as senior VP of investor relations, strategic planning
  • Google Health hires FDA’s chief digital health officer
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says

RSS From Medical Design & Outsourcing

  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS